Hepatitis E virus (HEV), family Hepeviridae, is a main cause of epidemic hepatitis in developing countries and sporadic and cluster cases of hepatitis in industrialized countries. There are an increasing number of reported cases in humans especially in industrialized countries, and there is a high potential for transboundary spread of zoonotic genotypes of the virus through the transport of pigs, pig products and byproducts. Bloodborne transmission of the virus has been reported with a significant medical concern. To better coordinate HEV research and design better control measures of HEV infections in animals, a group of HEV experts reviewed the current knowledge on the disease and considered the existing disease control tools. It was concluded that there is a lack of in-depth information about the spread of the virus from pigs to humans. The role of animals other than pigs in the zoonotic transmission of the virus to humans and the extent of foodborne transmission are poorly understood. Factors involved in development of clinical disease such as infectious dose, susceptibility and virulence of virus strains need to be studied more extensively. However, such studies are greatly hindered by the absence of a broadly applicable, efficient and sensitive in vitro cell culture system for HEV. Diagnostic tools for HEV are available but need to be further validated, harmonized and standardized. Commercially available HEV vaccines for the control of HEV infection in animal populations are needed as such vaccines can minimize the zoonotic risk for humans. Anti-HEV drugs for treatment of HEV-infected patients need to be studied more extensively. The detailed expert review can be downloaded from the project website at
| INTRODUCTION
According to the actual taxonomic classification scheme, all humanpathogenic hepatitis E virus (HEV) strains are grouped into the family Hepeviridae in the genus Orthohepevirus, species Orthohepevirus A (Smith et al., 2014) . HEV is a small virus generally considered to be non-enveloped; however, HEV particles in a membrane-associated, quasi-enveloped form have been recently identified in serum samples and cell culture supernatant (Yin, Ambardekar, Lu, & Feng, 2016) . The genome of HEV consists of a single-stranded, positivesense RNA with a size of approximately 7.2 Kb (Tam et al., 1991), which is capped at the 5 0 end and polyadenylated at the 3 0 end. It DISCONTOOLS (http://www.discontools.eu/) Hepatitis E virus expert group.
contains short stretches of untranslated regions (UTR) at both ends.
The HEV genome has three open-reading frames (ORFs): ORF1 encodes the non-structural polyprotein (nsp) that contains various functional units: methyltransferase (MeT), papain-like cysteine protease (PCP), macrodomain (X), RNA helicase (Hel) and RNA-dependent RNA polymerase (RdRp) (Chandra, Taneja, Kalia, & Jameel, 2008) . ORF2 encodes the viral capsid protein with an N-terminal signal sequence and glycosylation loci. Crystal structures of the recombinantly expressed capsid protein of HEV genotype 3 in insect cells revealed three functional domains: The S (shell) domain forms an icosahedral shell that serves as the base for arranging M (middle) and P (protruding) domains (Xing et al., 2010) . ORF3
encodes a small regulatory phosphoprotein with both structural and non-structural functions (Cao & Meng, 2012) .
HEV is a highly variable virus, and the Orthohepevirus A species contains at least four different genotypes (1-4) infecting humans (Smith et al., 2013; Smith et al., 2014) . The different HEV genotypes show a distinct geographical distribution (Lu, Li, & Hagedorn, 2006) . Genotypes 1 and 2 (HEV-1 and HEV-2) are restricted to humans and are prevalent in developing countries. Genotypes 3
and 4 (HEV-3 and HEV-4) are distributed worldwide, have a much wider host range and are considered to be zoonotic (Doceul, Bagdassarian, Demange, & Pavio, 2016) . HEV3 occurs in pigs worldwide, whereas HEV4 is mainly seen in Asia. Closely related viruses have been found in wild boar (genotypes 5 and 6) and camel (genotype 7) (Takahashi et al., 2014; Woo et al., 2014) . Other HEV-like viruses have been identified in chicken, rat, ferret, mink, fox, moose and bats (Johne et al., 2014) .
It is thought that hepatocytes are the primary site for HEV replication, although evidence of extrahepatic HEV replication has been reported (Billam et al., 2008; Williams et al., 2001 ). The exact receptor(s) on hepatocytes to which HEV binds remains unclear. Studies using an in vitro Huh-7 liver cell culture system indicate that heparin sulphate proteoglycans on the cell surface, particularly syndecans (of which syndecan-1 is the most abundant), can bind recombinant HEV ORF2 protein expressed as VLPs (Kalia, Chandra, Rahman, Sehgal, & Jameel, 2009 ). HEV-3 and HEV-4 infections in animals and avian HEV infection in chickens have been shown to replicate extrahepatically particularly in the small intestines (Billam et al., 2008; Williams et al., 2001) . Although HEV is a primarily hepatotropic virus, it may to some extent replicate in other tissues, as extrahepatic manifestations such as neurological symptoms, myosis as well as renal and haematological complications have been observed (Kamar, Dalton, Abravanel, & Izopet, 2014; Perrin et al., 2015) .
HEV can enter the body through ingestion with contaminated food or water. It is believed that the virus replicates in the epithelial cells of the small intestines before reaching the target organ, the liver. Once reaching the liver, the virus multiplies in the hepatocytes and causes liver injury. In animal studies, viral replication in hepatocytes appears about 7 days after inoculation (i.v.) and affects up to 70%-90% of hepatocytes. Continued hepatocyte damage leads to clinical illness after an average incubation period of 3 (range 2-10)
weeks. Viremia appears a few days before the onset of symptoms, attains its peak with that of serum transaminase levels, continues for a few weeks thereafter and is accompanied by faecal HEV excretion (Aggarwal, Kini, Sofat, Naik, & Krawczynski, 2000; Tsarev et al., 1992 (Zhou et al., 2015) . A single report described an HEV7 infection in an immunocompromised patient, who regularly consumed uncooked camel meat and milk (Lee et al., 2016) . In several countries, rabbit HEV strains which have a close sequence homology with HEV-3 strains have been reported, and a closely related strain was also identified in a human patient (Izopet et al., 2012) . Rabbit HEV originating from farmed rabbits in China has been shown experimentally to be able to infect both cynomolgus macaques and pigs (Han et al., 2014) .
HEV has also been detected in the environment in surface water, shellfish, manure and meat products, leafy green vegetables, soft fruits and spice (Doceul et al., 2016) . Primary transmission of the virus is through water and food particularly when faecally contaminated. In cell culture supernatant, infectious HEV could be detected after 1-month storage at room temperature and after more than 2 months storage at 4°C (Johne, Trojnar, Filter, & Hofmann, 2016) .
As a non-enveloped virus, HEV is very stable. Viable virus has also been detected in pork products, and HEV3 can survive a temperature of 60°C (Cook & Van der Poel, 2015) .
In animals, infection is considered to be asymptomatic. In contrast, infection in humans can vary from asymptomatic or mild dis- | 23 potentially increasing public health threat. How this effects mortality rates is not clearly known (Adlhoch et al., 2016) .
In Europe, hepatitis E is considered as a self-limiting acute hepatitis. More than 70% of infections, however, are asymptomatic and people only seroconvert (Guillois et al., 2016 arthralgia. Vomiting and diarrhoea also occur commonly. The incubation period is estimated to be between 2 and 6 weeks (up to 60 days), and clearance of infection is usually observed within 1-5 weeks (Lhomme et al., 2016) . The ALT level is usually 1,000-3,000 IU/L, but the range is wide. Some patients have a much more modest transaminitis, and ALT levels may be elevated in blood samples taken at the time of viremia (Kamar et al., 2014) . Hepatitis E mortality rates of 0.5%-4% occur in infected individuals in the general population, and the rate can exceed 20% in pregnant women in the case of HEV-1. For HEV-3 and HEV-4, this high mortality rate in pregnant women has not been observed. After superinfection in patients with underlying liver disease, convalescence can be poor.
Neurology symptoms relating to HEV-3 infection have also been reported more recently. The disorders can be divided into four main entities: mononeuritis multiplex, Parsonage-Turner syndrome, meningoradiculitis and acute demyelinating neuropathy (i.e., GuillainBarre) Perrin et al., 2015) . HEV-3 infections may also cause glomerular disease. Kidney injury due to HEV3 can be observed in immunocompetent as well as kidney or liver transplant patients (Kamar et al., 2012) . HEV infection has become a significant clinical problem in immunocompromised individuals, in particular organ transplant recipients. In such cases, HEV infection may become chronic with progression towards cirrhosis. All described chronic HEV cases have been observed in patients infected by HEV-3, were autochthonous and have not been associated with travel (Kamar et al., 2012) . To identify current gaps in the availability and quality of control tools and determine the research necessary to develop new or improved tools, a DISCONTOOLS group of experts on hepatitis E virus (HEV) reviewed the current knowledge on the disease and considered the existing disease control tools. In the absence of a reference test assessing HEV antibodies, the parallel use of two tests, ELISA and Western blot (WB), is recommended for use in testing human samples. In veterinary medicine, only one single ELISA test is usually applied as screening test (Thiry et al., 2014) . Recently, a veterinary serum standard has been developed which should assist with quality control and comparison of antibody-based HEV tests (Zhang et al., 2017) . 
| HEPATITIS E VIRUS D IAGN OSTICS

| HEPATITIS E VIRUS VACCINES
Hepatitis E virus vaccination would be most used in developing countries where HEV-1 virus is endemic, especially in high-risk groups such as pregnant women in the second and third trimesters, the elderly and children less than 2 years of age. The vaccine may also have a role in HEV outbreaks. In industrialized countries, vaccination may also be useful in high-risk groups such as blood transfusion recipients, animal handlers, food industry workers, immunocompromised patients and those with chronic liver disease, as well as travellers to endemic areas.
Two ORF2 protein expression products as vaccine candidates have been shown to be efficacious in phase II/III clinical trials (Shrestha et al., 2007; Zhu et al., 2010 ). An alternative approach is a DNA vaccine administered either alone or with the addition of protein to augment the immune response. The advantage of DNA vaccination is its stability and ease of preparation (Thomas & Arun, 2011; Haffar, Bazerbachi, & Lake, 2015) .
A 56-kDa truncated HEV ORF2 protein vaccine has undergone safety and efficacy studies in a randomized, double-blind, placebo controlled, phase II trial in the Nepalese Army sponsored by SmithKline
Beecham Biologicals (now GlaxoSmithKline: GSK, Brentford, UK). The vaccine was well tolerated and highly immunogenic, with 95.5% of the study subjects acquiring significant antibody titre (95% CI: 85.6-98.6) (Shrestha et al., 2007) . This study had several limitations, but resulted in publication of the first successful clinical trial of an efficacious HEV vaccine. However, this vaccine has not reached the market because of concerns regarding its ability to generate sufficient revenue.
A Chinese company (Xiamen Innovax Biotech, Xiamen, China) has developed another hepatitis E vaccine, designated as HEV 239
vaccine. HEV 239 is a 26-kDa protein encoded by ORF2 of HEV1, expressed in Escherichia coli, and presents as virus-like particles of 23 nm in diameter. This vaccine was tested in a large-scale, randomized, double-blind, placebo controlled, phase III trial in 11 townships in eastern China. (Zhu et al., 2010) . The vaccine was well tolerated and protected against clinical acute HEV, with an efficacy of 100% after the second and third dose (95% CI: 72.1-100.0). Another 3 years' follow-up data showed that the efficacy was 93.3% (95% CI: 78.6-97.9) and in 87% of the participants anti-HEV IgG antibodies persisted for at least 4.5 years (Zhang et al., 2015) . | 25 issues were observed, while further investigation is ongoing to confirm the safety of vaccine in this cohort (Wu, Li et al., 2012; Wu, Zhu et al., 2012) . Safety and efficacy in people younger than 15 years or older than 65 years were not assessed.
For HEV vaccine development in animals, there are studies ongoing but currently no vaccine is commercially available for use in animals. However, vaccination of pig herds could reduce concerns over food safety and zoonotic infection. Implementation of vaccination campaigns for such purpose is expected to be difficult because overt clinical signs after HEV infection are not observed in pigs, which means that pig producers will not be eager to spend resources on this kind of vaccination campaigns. Backer, Berto, McCreary, Martelli, and Van der Poel (2012) modelled HEV vaccination in swine production. Different effects of vaccination were explored separately.
When vaccination is not sufficient to eliminate the virus, a shorter mean infectious period decreases the fraction of infectious animals at slaughter age, whereas a reduced transmission rate parameter adversely increases it. With a reduced susceptibility, vaccination of animals at a later age can be a better strategy than early vaccination.
These effects should be taken into account in vaccine development and vaccination strategies.
| ANTI-HEV PHARMACE UTICALS
There are currently no clear indications for the treatment of acute hepatitis E. Acute HEV infection is usually self-limiting, and antiviral therapy will be limited to a very small minority of very high-risk cases. Despite concerns for side effects, ribavirin monotherapy or in combination with pegylated interferon alpha (ribavirin, alpha-interferon) for at least 3 months appeared to show significant efficacy in the treatment of chronic hepatitis E. 3. There is a lack of knowledge on possible waterborne transmissions in industrialized countries.
4. There are significant gaps in our knowledge regarding the survival of HEV in the environment (including food contact surfaces) and also regarding the effect of elimination procedures used.
It is not known whether HEV infection in swine populations
causes economic losses especially during co-infections with other swine agents (such as porcine circovirus type 2 and porcine reproductive respiratory syndrome virus) and whether there would be other benefits (besides reducing the risk of pork safety) in vaccinating commercially reared pigs.
6. There is a lack of knowledge concerning factors involved in development of clinical diseases such as infective dose, host susceptibility, dose-response relationship and virulence of strains. Research is hindered by the absence of a broadly applicable and efficient in vitro cell culture system for HEV.
7. The mechanism and immune correlates leading to the progression of HEV infection to chronic hepatitis E in immunocompromised individuals are unknown. 
